Bacterial clonal diagnostics as a tool for evidence-based empiric antibiotic selection

PLoS ONE

Volumn 12, Issue 3, 2017, Pages

  Tchesnokova, Veronika ^a   Avagyan, Hovhannes ^a,b   Rechkina, Elena ^b,c   Chan, Diana ^a   Muradova, Mariya ^a   Haile, Helen Ghirmai ^a   Radey, Matthew ^a   Weissman, Scott ^d   Riddell, Kim ^b   Scholes, Delia ^b   Johnson, James R ^e   Sokurenko, Evgeni V ^a,b  

^a UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

^b KAISER PERMANENTE   (United States)

^c ID Genomics Inc Inc   (United States)

^d SEATTLE CHILDREN S RESEARCH INSTITUTE   (United States)

^e UNIVERSITY OF MINNESOTA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

COTRIMOXAZOLE; QUINOLINE DERIVED ANTIINFECTIVE AGENT; ANTIINFECTIVE AGENT;

ADULT; AGED; ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; ANTIBIOTIC THERAPY; ARTICLE; BACTERIAL LOAD; BACTERIUM CULTURE; CLONAL VARIATION; COHORT ANALYSIS; DIAGNOSTIC PROCEDURE; DRUG USE; EMPIRIC ANTIBIOTIC THERAPY; ESCHERICHIA COLI; EVIDENCE BASED MEDICINE; FEMALE; HUMAN; MALE; NONHUMAN; OBSERVATIONAL STUDY; POLYMERASE CHAIN REACTION; PRESCRIPTION; PROSPECTIVE STUDY; SENSITIVITY AND SPECIFICITY; SINGLE NUCLEOTIDE POLYMORPHISM; URINARY TRACT INFECTION; BACTERIUM IDENTIFICATION; CLASSIFICATION; DRUG EFFECTS; ESCHERICHIA COLI INFECTIONS; GENE FREQUENCY; GENETICS; GENOTYPE; MICROBIOLOGY; PROCEDURES; URINARY TRACT INFECTIONS; URINE;

ANTI-BACTERIAL AGENTS; BACTERIAL TYPING TECHNIQUES; COHORT STUDIES; DRUG RESISTANCE, BACTERIAL; ESCHERICHIA COLI; ESCHERICHIA COLI INFECTIONS; EVIDENCE-BASED MEDICINE; GENE FREQUENCY; GENOTYPE; HUMANS; POLYMERASE CHAIN REACTION; POLYMORPHISM, SINGLE NUCLEOTIDE; SENSITIVITY AND SPECIFICITY; TRIMETHOPRIM, SULFAMETHOXAZOLE DRUG COMBINATION; URINARY TRACT INFECTIONS;

EID: 85016243103     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0174132     Document Type: Article

References (40)

1. Johnson CC. Definitions, classification, and clinical presentation of urinary tract infections. Med Clin North Am. 1991; 75(2):241-52. PMID: 1996031.
2. Little P, Merriman R, Turner S, Rumsby K, Warner G, Lowes JA, et al. Presentation, pattern, and natural course of severe symptoms, and role of antibiotics and antibiotic resistance among patients presenting with suspected uncomplicated urinary tract infection in primary care: observational study. BMJ. 2010; 340:b5633. https://doi.org/10.1136/bmj.b5633 PMID: 20139213.
3. Saint S. Clinical and economic consequences of nosocomial catheter-related bacteriuria. Am J Infect Control. 2000; 28(1):68-75. PMID: 10679141.
4. Wilson ML, Gaido L. Laboratory diagnosis of urinary tract infections in adult patients. Clin Infect Dis. 2004; 38(8):1150-8. https://doi.org/10.1086/383029 PMID: 15095222.
5. Flores-Mireles AL, Walker JN, Caparon M, Hultgren SJ. Urinary tract infections: epidemiology, mechanisms of infection and treatment options. Nat Rev Microbiol. 2015; 13(5):269-84 https://doi.org/10.1038/nrmicro3432 PMID: 25853778.
6. Foxman B. The epidemiology of urinary tract infection. Nat Rev Urol. 2010; 7(12):653-60 https://doi.org/10.1038/nrurol.2010.190 PMID: 21139641.
7. Foxman B. Urinary tract infection syndromes: occurrence, recurrence, bacteriology, risk factors, and disease burden. Infect Dis Clin North Am. 2014; 28(1):1-13. https://doi.org/10.1016/j.idc.2013.09.003 PMID: 24484571.
8. Schappert SM, Rechtsteiner EA. Ambulatory medical care utilization estimates for 2007. Vital Health Stat 13. 2011;(169):1-38.
9. Gopal Rao G, Patel M. Urinary tract infection in hospitalized elderly patients in the United Kingdom: the importance of making an accurate diagnosis in the post broad-spectrum antibiotic era. J Antimicrob Chemother. 2009; 63(1):5-6. https://doi.org/10.1093/jac/dkn458 PMID: 19022779.
10. Falagas ME, Kotsantis IK, Vouloumanou EK, Rafailidis PI. Antibiotics versus placebo in the treatment of women with uncomplicated cystitis: A meta-analysis of randomized controlled trials. J Infect. 2009; 58 (2):91-102. https://doi.org/10.1016/j.jinf.2008.12.009 PMID: 19195714.
11. Gupta K, Hooton TM, Naber KG, Wullt B, Colgan R, Miller LG, et al. International clinical practice guidelines for the treatment of acute uncomplicated cystitis and pyelonephritis in women: A 2010 update by the Infectious Diseases Society of America and the European Society for Microbiology and Infectious Diseases. Clin Infect Dis. 2011; 52(5):e103-20. https://doi.org/10.1093/cid/ciq257 PMID: 21292654.
12. Caterino JM, Weed SG, Espinola JA, Camargo CA Jr. National trends in emergency department antibiotic prescribing for elders with urinary tract infection, 1996-2005. Acad Emerg Med. 2009; 16(6):500-7. https://doi.org/10.1111/j.1553-2712.2009.00353.x PMID: 19245373.
13. Johnson L, Sabel A, Burman WJ, Everhart RM, Rome M, MacKenzie TD, et al. Emergence of fluoroquinolone resistance in outpatient urinary Escherichia coli isolates. Am J Med. 2008; 121(10):876-84. https://doi.org/10.1016/j.amjmed.2008.04.039 PMID: 18823859.
14. Naber KG, Schito G, Botto H, Palou J, Mazzei T. Surveillance study in Europe and Brazil on clinical aspects and Antimicrobial Resistance Epidemiology in Females with Cystitis (ARESC): implications for empiric therapy. Eur Urol. 2008; 54(5):1164-75. https://doi.org/10.1016/j.eururo.2008.05.010 PMID: 18511178.
15. Taur Y, Smith MA. Adherence to the Infectious Diseases Society of America guidelines in the treatment of uncomplicated urinary tract infection. Clin Infect Dis. 2007; 44(6):769-74. https://doi.org/10.1086/511866 PMID: 17304445.
16. Ali MH, Kalima P, Maxwell SR. Failure to implement hospital antimicrobial prescribing guidelines: A comparison of two UK academic centres. J Antimicrob Chemother. 2006; 57(5):959-62. https://doi.org/10.1093/jac/dkl076 PMID: 16531431.
17. Hecker MT, Fox CJ, Son AH, Cydulka RK, Siff JE, Emerman CL, et al. Effect of a stewardship intervention on adherence to uncomplicated cystitis and pyelonephritis guidelines in an emergency department setting. PLoS One. 2014; 9(2):e87899. https://doi.org/10.1371/journal.pone.0087899 PMID: 24498394.
18. Grigoryan L, Zoorob R, Wang H, Trautner BW. Low Concordance With Guidelines for Treatment of Acute Cystitis in Primary Care. Open Forum Infect Dis. 2015; 2(4):ofv159. https://doi.org/10.1093/ofid/ofv159 PMID: 26753168.
19. Tchesnokova V, Avagyan H, Billig M, Chattopadhyay S, Aprikian P, Chan D, et al. A Novel 7-Single Nucleotide Polymorphism-Based Clonotyping Test Allows Rapid Prediction of Antimicrobial Susceptibility of Extraintestinal Directly From Urine Specimens. Open Forum Infect Dis. 2016; 3(1):ofw002. https://doi.org/10.1093/ofid/ofw002 PMID: 26925427.
20. Tchesnokova V, Billig M, Chattopadhyay S, Linardopoulou E, Aprikian P, Roberts PL, et al. Predictive diagnostics for Escherichia coli infections based on the clonal association of antimicrobial resistance and clinical outcome. J Clin Microbiol. 2013; 51(9):2991-9. https://doi.org/10.1128/JCM.00984-13 PMID: 23843485.
21. Price LB, Johnson JR, Aziz M, Clabots C, Johnston B, Tchesnokova V, et al. The epidemic of extendedspectrum- beta-lactamase-producing Escherichia coli ST131 is driven by a single highly pathogenic subclone, H30-Rx. MBio. 2013; 4(6):e00377-13. https://doi.org/10.1128/mBio.00377-13 PMID: 24345742.
22. Fridkin SK, Hill HA, Volkova NV, Edwards JR, Lawton RM, Gaynes RP, et al. Temporal changes in prevalence of antimicrobial resistance in 23 US hospitals. Emerg Infect Dis. 2002; 8(7):697-701 https://doi.org/10.3201/eid0807.010427 PMID: 12095437.
23. Guyomard-Rabenirina S, Malespine J, Ducat C, Sadikalay S, Falord M, Harrois D, et al. Temporal trends and risks factors for antimicrobial resistant Enterobacteriaceae urinary isolates from outpatients in Guadeloupe. BMC Microbiol. 2016; 16(1):121. https://doi.org/10.1186/s12866-016-0749-9PMID: 27342199.
24. Swami SK, Banerjee R. Comparison of hospital-wide and age and locationstratified antibiograms of S. aureus, E. coli, and S. pneumoniae: Age- And location-stratified antibiograms. Springerplus. 2013; 2 (1):63. https://doi.org/10.1186/2193-1801-2-63 PMID: 23487499.
25. CLSI. Performance Standards for Antimicrobial Susceptibility Testing; Twentieth Information Supplement. 2010.
26. Hooton TM, Roberts PL, Cox ME, Stapleton AE. Voided midstream urine culture and acute cystitis in premenopausal women. N Engl J Med. 2013; 369(20):1883-91. https://doi.org/10.1056/NEJMoa1302186 PMID: 24224622.
27. Shin J, Kim J, Wie SH, Cho YK, Lim SK, Shin SY, et al. Fluoroquinolone resistance in uncomplicated acute pyelonephritis: epidemiology and clinical impact. Microb Drug Resist. 2012; 18(2):169-75. https://doi.org/10.1089/mdr.2011.0139 PMID: 22400491.
28. Johnson JR, Thuras P, Johnston BD, Weissman SJ, Limaye AP, Riddell K, et al. The Pandemic H30 Subclone of Escherichia coli Sequence Type 131 Is Associated With Persistent Infections and Adverse Outcomes Independent From Its Multidrug Resistance and Associations With Compromised Hosts. Clin Infect Dis. 2016; 62(12):1529-36. https://doi.org/10.1093/cid/ciw193 PMID: 27025834.
29. Talan DA, Stamm WE, Hooton TM, Moran GJ, Burke T, Iravani A, et al. Comparison of ciprofloxacin (7 days) and trimethoprim-sulfamethoxazole (14 days) for acute uncomplicated pyelonephritis pyelonephritis in women: A randomized trial. JAMA. 2000; 283(12):1583-90. PMID: 10735395.
30. Caliendo AM, Gilbert DN, Ginocchio CC, Hanson KE, May L, Quinn TC, et al. Better tests, better care: improved diagnostics for infectious diseases. Clin Infect Dis. 2013; 57 Suppl 3:S139-70.
31. ECDC. Transatlantic Task Force on Antimicrobial Resistance Report on the Joint EU-US Workshop: challenges and solutions in the development of new diagnostic tests to combat antimicrobial resistance. 2011.
32. Brolund A, Sundqvist M, Kahlmeter G, Grape M. Molecular characterisation of trimethoprim resistance in Escherichia coli and Klebsiella pneumoniae during a two year intervention on trimethoprim use. PLoS One. 2010; 5(2):e9233. https://doi.org/10.1371/journal.pone.0009233 PMID: 20169085.
33. Shin HW, Lim J, Kim S, Kim J, Kwon GC, Koo SH. Characterization of trimethoprim-sulfamethoxazole resistance genes and their relatedness to class 1 integron and insertion sequence common region in gram-negative bacilli. J Microbiol Biotechnol. 2015; 25(1):137-42. PMID: 25348695.
34. Redgrave LS, Sutton SB, Webber MA, Piddock LJ. Fluoroquinolone resistance: mechanisms, impact on bacteria, and role in evolutionary success. Trends Microbiol. 2014; 22(8):438-45. https://doi.org/10.1016/j.tim.2014.04.007 PMID: 24842194.
35. Hooper DC. Emerging mechanisms of fluoroquinolone resistance. Emerg Infect Dis. 2001; 7(2):337- 41. https://doi.org/10.3201/eid0702.700337 PMID: 11294736.
36. Johnson JR, Porter SB, Thuras P, Johnson TJ, Price LB, Tchesnokova V, et al. Greater ciprofloxacin tolerance as a possible selectable phenotype underlying the pandemic spread of the H30 subclone of Escherichia coli sequence type 131. Antimicrob Agents Chemother. 2015; 59(11):7132-5. https://doi.org/10.1128/AAC.01687-15PMID: 26324269.
37. Johnson JR, Johnston B, Kuskowski MA, Sokurenko EV, Tchesnokova V. Intensity and Mechanisms of Fluoroquinolone Resistance within the H30 and H30Rx Subclones of Escherichia coli Sequence Type 131 Compared with Other Fluoroquinolone-Resistant E. coli. Antimicrob Agents Chemother. 2015; 59 (8):4471-80. https://doi.org/10.1128/AAC.00673-15PMID: 25987621.
38. Lawrenson RA, Logie JW. Antibiotic failure in the treatment of urinary tract infections in young women. J Antimicrob Chemother. 2001; 48(6):895-901. PMID: 11733475.
39. Gupta K, Stamm WE. Outcomes associated with trimethoprim/sulphamethoxazole (TMP/SMX) therapy in TMP/SMX resistant community-acquired UTI. Int J Antimicrob Agents. 2002; 19(6):554-6. PMID: 12135847.
40. WHO. WHO Global Strategy for Containment of Antimicrobial Resistance. World Health Organization, 2001.